Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.55 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.55 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.55 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.55 |
| ▸ | HTR3B | O95264 | 1/20 | 0.55 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.55 |
| ▸ | CHRNG | P07510 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3262479 | 0.86 | ALDH1A1 (0.71) | ALDH1A1KDM4ETDP1KMT2AMEN1 | |
| SCHEMBL524920 | 0.85 | ALDH1A1 (0.66) | ALDH1A1KDM4ETDP1KMT2AMEN1 | |
| SCHEMBL173281 | 0.83 | ALDH1A1 (0.63) | ALDH1A1KDM4ETDP1KMT2AMEN1 | |
| SCHEMBL2683364 | 0.82 | ALDH1A1 (0.61) | ALDH1A1KDM4ETDP1KMT2AMEN1 | |
| SCHEMBL29980501 | 0.82 | ALDH1A1 (0.72) | ALDH1A1KDM4ETDP1KMT2AMEN1 | |
| SCHEMBL3369061 | 0.79 | ALDH1A1 (0.61) | ALDH1A1KDM4ETDP1KMT2AMEN1 | |
| SCHEMBL854070 | 0.79 | ALDH1A1 (0.61) | ALDH1A1KDM4ETDP1KMT2AMEN1 | |
| SCHEMBL29683697 | 0.79 | ALDH1A1 (0.66) | ALDH1A1KDM4ETDP1KMT2AMEN1 | |
| SCHEMBL20590950 | 0.79 | ALDH1A1 (0.62) | ALDH1A1KDM4ETDP1KMT2AMEN1 | |
| SCHEMBL157171 | 0.79 | ALDH1A1 (0.66) | ALDH1A1KDM4ETDP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994443-B2 | Modified nicotinic compounds and related methods | SELECTA BIOSCIENCES, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| EP-2640190-A1 | MODIFIED NICOTINIC COMPOUNDS AND RELATED METHODS | Selecta Biosciences, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012061717-A1 | MODIFIED NICOTINIC COMPOUNDS AND RELATED METHODS | SELECTA BIOSCIENCES, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120114677-A1 | MODIFIED NICOTINIC COMPOUNDS AND RELATED METHODS | SELECTA BIOSCIENCES, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114677-A1 | MODIFIED NICOTINIC COMPOUNDS AND RELATED METHODS | NNMT, CHRNG, CHRM5 | ALDH1A1 1321/4885KDM4E 866/4885TDP1 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.